<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.14003.005</object-id><label>Table 2.</label><caption><p>Summary of time to treatment failure by <italic>Salmonella</italic> Typhi lineage and ciprofloxacin susceptibility.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.14003.005">http://dx.doi.org/10.7554/eLife.14003.005</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time to treatment failure</th><th>Gatifloxacin (events/N)</th><th>Ceftriaxone (events/N)</th><th>Hazard ratio of time to failure (95%CI); p value</th><th>Heterogeneity test <break/>(p value)</th></tr></thead><tbody><tr><td>H58*</td><td/><td/><td/><td>0.020</td></tr><tr><td>- H58</td><td>15/34</td><td>3/31</td><td>0.19&#160;(0.05, 0.56); p=0.002</td><td/></tr><tr><td>- Non-H58</td><td>0/6</td><td>2/7</td><td>3.87&#160;(0.31, 534.24); p=0.32</td><td/></tr><tr><td>Ciprofloxacin susceptibility group<sup>&#8224;</sup></td><td/><td/><td/><td>0.08</td></tr><tr><td>- Susceptible</td><td>0/5</td><td>1/5</td><td>2.40&#160;(0.13,&#160;350.21); p=0.57</td><td/></tr><tr><td>- Intermediate</td><td>7/25</td><td>2/27</td><td>0.27&#160;(0.05,&#160;0.99); p=0.049</td><td/></tr><tr><td>- Resistant</td><td>8/10</td><td>2/6</td><td>0.27&#160;(0.05, 1.01); p=0.052</td><td/></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p>*Likelihood ratio test p=0.06 and 0.40 for comparison of time to treatment failure between H58 vs. non-H58 groups in gatifloxacin arm only and in all patients, respectively</p></fn><fn id="tblfn6"><p><sup>&#8224;</sup>Likelihood ratio test p=0.007 for comparison of time to treatment failure between MIC groups in gatifloxacin arm only</p></fn></table-wrap-foot></table-wrap>